Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Scavenger mRNA decapping enzyme DcpS is a member of the histidine triad (HIT) family of hydrolases that plays a key role in eukaryotic mRNA turnover. It hydrolyzes the residual 5' cap structure (m^7^GpppN) from short mRNA fragments produced after 3' to 5' exonucleolytic degradation by the exosome complex, thus preventing the accumulation of cap structures and contributing to overall mRNA decay and gene expression regulation. DcpS acts only on short capped fragments, not on intact mRNA, through a substrate length-sensing mechanism. The enzyme is mainly nuclear, but it shuttles between nucleus and cytoplasm, modulates cap-dependent RNA splicing events via interaction with the cap-binding complex, and defines the HIT motif as a new mRNA decapping domain. DcpS is not to be confused with Dcp2, which acts on full-length mRNA. There are no clinically approved drugs directly targeting DcpS as of the latest reports. No established role as a patient biomarker or specific therapeutic safety concerns in current literature.
Hydrolyzes residual 5' cap structures (m^7^GpppN) of short mRNA fragments; Removes cap after 3'->5' exonucleolytic degradation by the exosome complex
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Scavenger mRNA decapping enzyme DcpS (DcpS).